Transcatheter Closure of Patent Foramen Ovale in Thrombophilia Patients

The transcatheter treatment of patent foramen ovale (PFO) has been shown to reduce thromboembolic events in patients with cryptogenic stroke. However, most of large randomized studies have failed to include patients with thrombophilia, either inherited or acquired. For instance, the RESPECT study excluded patients with antiphospholipid antibodies (AFA) or hyperhomocysteinemia, while the REDUCE screened for AFA and only excluded patients with anticoagulation indication. 

Cierre percutáneo de foramen oval permeable, en pacientes con trombofilia

It is important to highlight that thrombophilia is common among patients with cryptogenic stroke. In the absence of other prolonged anticoagulation indication, PFO closure might result beneficial to reduce the risk of stroke or paradoxical thromboembolism in these patients. Nevertheless, we should still bear in mind these patients with thrombophilia also present a higher risk of procedure related complications and higher risk of thromboembolic events, both arterial and venous. In fact, the presence of thrombophilia alone has been associated with higher incidence of stroke or transient ischemic attack after PFO closure. 

The aim of this study was to assess the differences between events in patients undergoing transcatheter PFO closure driven by cryptogenic shock, paradoxical thromboembolism or deep vein thrombosis (DVP) / lung thromboembolism (LTE) at Toronto General Hospital between 1999 and 2017. Outcomes were assessed at 30 days, including hospitalization for observation and hospitalizations, as well as long term outcomes, which included TIA, stroke, acute MI, major bleeding, DVP / LTE, new septal procedure and death. 

Read also: TAVR in Asymptomatic or Minimally Symptomatic Patients: 30-Day Results.

Data from 660 patients undergoing PFO closure were gathered; patient mean age was 56.4, and 63% were treated with Amplatzer. 97.9% of patients received PFO closure driven by cryptogenic shock, while in the rest it was driven by DVT/LTE. Thrombophilia was diagnosed in 26% of cohort patients and most cases presented acquired mutations. In general, there were no significant baseline differences between the group, except for the presence of migraines, which was higher in thrombophilia patients. (26% vs. 34%; P=0.04).

Most patients had a short stay and were discharged the same day of the procedure (91.2%). Complications were registered in 2.9% of cases, including vascular lesions (fewer than 5), arrhythmias requiring treatment (15 or more) and device embolization (fewer than 5). 

Looking at long term events, we observed that 19.5% of cases had at least one visit to the observation unit. During treatment, dual antiplatelet treatment (DAPT) was prescribed to 61% of patients with thrombophilia and 68.8% of patients without thrombophilia. Mean cohort followup was 11.6 years and the most common events were atrial fibrillation (1.0 every 100 persons/year; CI 95% 0.8-1.2), followed by new ACV/AIT (0.8 every 100 persons/year; CI 95%: 0.6-1.1). 

Read also: Treatment and Gender-Based Outcomes for Coronary Bifurcation Stent Placement: Report from the e-ULTIMASTER Registry.

There were no significant differences in the studied adverse events between patients with and without thrombophilia. (Log-Rank test P = 0.4924).

Conclusions

This observational study including one quarter of patients with thrombophilia did not find significant differences in cerebrovascular event recurrence between patients with and without thrombophilia at long term. 

These studies support the indication and potential use of POF closure in patients with thrombophilia, despite their prior exclusion from large randomized studies. 

Dr. Omar Tupayachi

Dr. Omar Tupayachi.
Member of the Editorial Board of SOLACI.org.

Original Title: Short- and Long-Term Outcomes in Patients With Thrombophilia Undergoing Transcatheter Closure of Patent Foramen Ovale.

Reference: Abrahamyan, Lusine et al. “Short- and Long-Term Outcomes in Patients With Thrombophilia Undergoing Transcatheter Closure of Patent Foramen Ovale.” JACC. Cardiovascular interventions vol. 16,11 (2023): 1360-1366. doi:10.1016/j.jcin.2023.04.027.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

TAVR in Small Annuli: What Valve Should We Use?

One of the major challenges of severe aortic stenosis are patients with small aortic annuli, defined as ≤430 mm² aortic valve area. This condition...

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...

ACC 2025 | BHF PROTECT-TAVI: Are Cerebral Protection Systems Necessary in TAVI?

TAVI has seen a steady increase in use, though stroke continues to be one of its unwanted complications, mostly ischemic and, less frequently, hemorrhagic. The...

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

SMART-CHOICE 3 | Efficacy and Safety of Clopidogrel vs Aspirin Monotherapy in High Risk Patients after Percutaneous Coronary Intervention

Courtesy of Dr. Juan Manuel Pérez. After post percutaneous coronary intervention (PCI) standard duration dual antiplatelet therapy (DAPT), the optimal long term monotherapy strategy is...

RACE Trial: Effect of Balloon Pulmonary Angioplasty and Riociguat on Right Ventricular Afterload and Function in Chronic Thromboembolic Pulmonary Hypertension

Even though pulmonary endarterectomy is the treatment of choice for chronic thromboembolic pulmonary hypertension (CTEPH), up to 40% of patients are not candidates because...

iFR- vs. FFR-Guided Coronary Revascularization: 5-Year Clinical Outcomes

The assessment of coronary stenosis using coronary physiology has become a key tool in guiding revascularization. The two most widely used techniques are fractional...